Interleukin-16 and vascular endothelial growth factor in the serum of bone tumor patients

The results of studies of interleukin 16 (IL-16) and vascular endothelial growth factor (VEGF) by ELIsa in the serum of patients with primary malignant tumors of bone and healthy age-matched to identify the possible correlation with the histological structure of the tumor and prognosis of the disease were presents. It is shown that the detection rate of IL-16 in serum in bone tumors was 93%, no significant differences in levels of IL-16 in considering the histological structure of tumor is not revealed. relationship between the size of the primary tumor and the content of IL-16 in serum were not found. overall 3- and 5-year survival of patients with malignant bone tumors content IL-16 in serum >33.0 pg/ml was significantly lower than patients with levels of IL-16 <33.0 pg/ml. osteosarcoma overall 5-year survival in patients with high IL-16 in serum was 1.6 times, with Ewing’s sarcoma in 1.7 times, chondrosarcoma – 1.8 times lower than in patients with the content IL-16 in serum <33.0 pg/ml. malignant bone tumors, VEGF levels were significantly higher than in borderline and benign tumors, statistical analysis of significant differences in the levels of VEGF in view of the morphological structure of the primary tumor has not revealed. maximum values VEGF marked with periosteal osteosarcoma, minimum – at paraosteal osteosarcoma – osteosarcoma with a favorable prognosis. when the content of IL-16 >33.0 pg/ml, which to our knowledge has been less favorable prognosis than patients with lower levels of IL-16, VEGF levels in the serum in all morphological variants of the structure of the primary tumor were higher than with IL-16 levels <33.0 pg/ml, but the differences were not statistically significant. In healthy people marked inverse relationship between the levels of VEGF and IL-16 in serum (r=–0.34), in benign tumors – a direct correlation (r=0.46), which is possible due to the peculiarities of the growth of the tumors. Initially high rates of IL-16 to meet the high values of VEGF in serum (p<0.05). Indicators of overall 3- and 5-year survival in patients with bone sarcomas levels of VEGF >493 pg/ml in serum were significantly lower than among those with low values of VEGF (<493 pg/ml; p<0.05). osteosarcoma no significant differences in the 3- and 5-year overall survival for baseline values of VEGF in blood serum. when Ewing sarcoma and chondrosarcoma of bone were significant differences in the 3- and 5-year overall survival, which depended on the baseline VEGF. Greatest figures 3 and 5-year overall survival observed in patients with bone sarcomas containing IL-16 <33 pg/ml VEGF <493 pg/ml and at least baseline IL-16 <33 pg/ml VEGF >493 pg/ml (p<0,05).